Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company focused on developing treatments that target protein growth factors at the cell surface. The company has no approved products and generates no product revenue, funding operations through equity offerings, an at-the-market (ATM) share program, and a debt facility. Its lead program is apitegromab, a selective inhibitor of myostatin activation being developed for spinal muscular atrophy (SMA). As of December 31, 2025, Scholar Rock had raised $91.7 million in net proceeds from its ATM program and $50.0 million from a debt facility during FY2025, with financing activities totaling $228.4 million for the year. The company is headquartered in Massachusetts and is seeking marketing approval for apitegromab. Cash from operations is consumed entirely by research and development spending, with investing activities providing $218.7 million in FY2025, primarily from marketable securities transactions.

Revenue model

Scholar Rock generates no product revenue as of the FY2025 10-K filing. Operations are funded through equity capital markets, including an ATM common share program ($91.7 million net proceeds in FY2025), warrant exercises ($63.8 million in FY2025), stock option exercises ($23.8 million in FY2025), and a debt facility ($50.0 million drawn in FY2025). The company may also enter collaboration, strategic alliance, or licensing agreements as a potential future revenue source.

Products and services

Apitegromab is Scholar Rock's lead product candidate, a selective inhibitor targeting myostatin activation, in development for spinal muscular atrophy (SMA). The company is actively seeking FDA marketing approval for apitegromab as of the 10-K filed 2026-03-03. No products are approved or commercially available.

Customers and end markets

The end market is patients with spinal muscular atrophy (SMA), a rare neuromuscular disease. If approved, the product would be subject to government reimbursement programs including Medicare Part D and Medicaid, as well as private payors. No commercial customers exist as of the FY2025 filing date.

Value-chain role

Scholar Rock operates as a drug discovery and clinical-stage development company. Manufacturing is outsourced to third-party contract manufacturers operating under FDA current Good Manufacturing Practice (cGMP) regulations. The company does not own manufacturing facilities and relies on external vendors for research, clinical trial execution, and commercial-scale manufacturing activities.

Geographic exposure

Scholar Rock is headquartered in Massachusetts. Regulatory submissions target the FDA in the United States and the EMA in Europe. Data privacy obligations include compliance with HIPAA, the California Consumer Privacy Act (CCPA), and the EU General Data Protection Regulation (GDPR), indicating clinical operations or data handling across the United States and European Economic Area.

Source: SEC 10-K, filed 2026-03-03

Industry: Biological Products, (No Diagnostic Substances) Peers: Invivyd Inc Anika Therapeutics Inc Arcturus Therapeutics Holdings Inc Atara Biotherapeutics Inc Kalvista Pharmaceuticals Inc Eiger BioPharmaceuticals, Inc. Karyopharm Therapeutics Inc Monte Rosa Therapeutics Inc Vigil Neuroscience, Inc.